Online citations, reference lists, and bibliographies.
← Back to Search

Observational Study On Safety And Tolerability Of Duloxetine In The Treatment Of Female Stress Urinary Incontinence In German Routine Practice.

M. Michel, A. Minarzyk, I. Schwerdtner, D. Quail, H. D. Methfessel, Hans-Joachim Weber
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
AIMS To evaluate the safety and tolerability of duloxetine during routine clinical care in women with stress urinary incontinence (SUI) in Germany, and in particular, to identify previously unrecognized safety issues as uncommon adverse reactions, and the influence of confounding factors present in clinical practice on the safety profile of duloxetine. METHODS Office-based urologists, gynaecologists and primary care physicians were asked to document women newly started on treatment for moderate to severe symptoms of SUI. Six thousand eight hundred and fifty-four patients from urologist/gynaecologist practices and 5879 primary care patients were assessed. In a two-armed, observational study with parallel 12 week (urologists and gynaecologists) or 24 week (primary care physicians) design, patients were treated with duloxetine or other conservative treatment. The main outcome measure was the occurrence of adverse events (AEs). RESULTS Baseline characteristics differed slightly between patient groups and studies. Duloxetine doses in most patients were lower than recommended. Overall, AE frequency with duloxetine was lower than in controlled studies (15.9% (95% CI 14.9, 16.9) and 9.1% (95% CI 8.2, 10.0) in the 12 and 24 week treatment groups, respectively), but exhibited a similar qualitative spectrum. In the logistic regression models, the following factors were associated with greater AE risk: investigator specialization (gynaecologist vs. urologist and primary care physician), initial duloxetine dose (80 vs. 20 mg day(-1) ) and use of any concomitant medication. Within the 24 week study, a positive screen for depressive disorder was surprisingly common, but no case of attempted suicide was reported in either study. CONCLUSIONS Our results from German clinical practice show that women with SUI were often treated with duloxetine doses lower than recommended. This was associated with a low incidence of AEs. Suicide attempts were not reported.
This paper references
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.
P. Abrams (2002)
Facilitatory neuromodulative effect of duloxetine on pudendal motor neurons controlling the urethral pressure: a functional urodynamic study in healthy women.
S. Boy (2006)
Cardiovascular Safety and Overall Tolerability of Solifenacin in Routine Clinical Use
M. Michel (2008)
Serious suicide attempt with duloxetine treatment.
R. Reeves (2008)
The incidence of urinary incontinence across Asian, black, and white women in the United States.
M. Townsend (2010)
The pharmacological treatment of urinary incontinence
Andersson (1999)
An Evaluation of the Cardiovascular Safety Profile of Duloxetine
J. Wernicke (2007)
Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats.
M. Katofiasc (2002)
Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder.
M. Michel (2005)
Duloxetine vs Placebo in the Treatment of Stress Urinary Incontinence: A Four-Continent Randomized Clinical Trial
A. Wein (2004)
Duloxetine versus placebo in the Duloxetine tolerability and safety
M Slack
Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence
D. Castro-Diaz (2006)
Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration
M. Stone (2009)
Does gender or age affect the efficacy and safety of tolterodine?
M. Michel (2002)
Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials
D. Fergusson (2005)
Duloxetine in the Treatment of Stress Urinary Incontinence
M. Michel (2005)
Pharmacological Treatment of Women Awaiting Surgery for Stress Urinary Incontinence
L. Cardozo (2004)
Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence.
R. Dmochowski (2003)
Duloxetine and suicide attempts: a possible relation
B. A. Salem (2008)
The impact on health‐related quality of life of stress, urge and mixed urinary incontinence
K. Coyne (2003)
Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety.
D. J. Hurley (2006)
Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials
A. Wein (2005)
A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence.
G. Ghoniem (2005)
Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat.
K. Thor (1995)
Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence
P. Kerrebroeck (2004)
Understanding the burden of stress urinary incontinence in Europe: a qualitative review of the literature.
C. Hampel (2004)
How are women with SUI‐symptoms treated with duloxetine in real life practice? – Preliminary results from a large observational study in Germany
M. Manning (2009)
Mixed Urinary Incontinence Symptoms: Urodynamic Findings, Incontinence Severity, and Treatment Response
R. Bump (2003)
The prevalence of urinary incontinence in women in four European countries
S. Hunskaar (2004)
Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary basis of approval reports.
A. Khan (2007)
Duloxetine versus placebo in the treatment of stress urinary incontinence.
P. Norton (2002)
Ambivalence over Emotional Expressiveness: psychometric evaluation of the AEQ-G18 in a representative German survey
C. Albani (2007)
Difference in quality of life in women with urge urinary incontinence compared to women with stress urinary incontinence
M. Schimpf (2009)
Depressivitäts-Screening – zwei Fragen für die Praxis
N. Grulke (2005)
The impact of the overactive bladder on health‐related utility and quality of life
C. Currie (2006)
Profile of Adverse Events with Duloxetine Treatment
S. Brunton (2010)
Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?
T. Schneider (2010)
Does the Number of Previous Vaginal Deliveries Affect Overactive Bladder Symptoms and their Response to Treatment?
Lambertus P.W. Witte (2008)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar